Hosted by the American Heart Association Center for Technology & Innovation, the competition seeks technologies capable of changing how conditions such as high blood pressure, stroke and heart failure are prevented, detected and treated. The program is positioned at the intersection of biomedical research, clinical medicine, data science and health-system operations. By connecting innovators with clinicians, researchers and investors, the Association aims to shorten the distance between a validated prototype and a tool that can be deployed at scale, particularly in communities where limited access, workforce shortages and rising costs continue to delay care.

The need for scalable cardiovascular technologies is underscored by the global burden of disease. Cardiovascular disease remains the leading cause of death worldwide, while health systems are confronting increasing demand for care and persistent shortages of trained personnel. Digital tools can help address those pressures by collecting physiological data outside conventional clinics, identifying risk patterns earlier and supporting clinicians with continuously updated information. Remote monitoring devices, for example, can transmit blood pressure, heart-rate or other patient measurements for analysis between visits. Artificial intelligence systems may then detect trends or abnormalities, although their clinical usefulness depends on the quality of the data, the reliability of the algorithms and the ability of medical teams to act on the results.

Five finalists will present their technologies at Scientific Sessions 2026, the American Heart Association’s flagship international meeting for cardiovascular science and clinical advancement. The event will take place Nov. 6–9 at McCormick Place in Chicago, with the finalists scheduled to deliver live pitches Nov. 7–8. The winner will be announced Nov. 9. Before reaching the stage, applicants will be evaluated on the maturity of their technology, the strength of available clinical or pilot data, the viability of their business model and the potential to improve outcomes across different care settings. Applications remain open through Sept. 18, and the five finalists are scheduled to be announced Oct. 10.

The competition’s emphasis on clinical validation distinguishes it from many startup contests that focus primarily on technical novelty, investment potential or rapid market growth. A health technology intended for cardiovascular care must function within complex clinical workflows, where decisions can have immediate consequences. Developers may need to demonstrate that a system produces accurate measurements, limits false alarms, protects patient information and performs consistently across different populations and devices. They must also show how clinicians will interpret its outputs, how patients will be engaged and how the technology can integrate with electronic health records, telehealth platforms or existing monitoring systems without creating additional burdens for already strained care teams.

Artificial intelligence is likely to be an important component of many emerging health technologies, but the Association’s criteria reflect the growing recognition that algorithmic performance must be evaluated in context. A model that performs well in a controlled dataset may behave differently when exposed to incomplete records, inconsistent measurements or populations that were underrepresented during development. Clinical validation can reveal whether an algorithm improves diagnosis, treatment selection, adherence or patient outcomes rather than merely predicting a condition. For cardiovascular and brain health applications, the most meaningful evidence may include reductions in hospitalizations, faster treatment after stroke, improved blood-pressure control or earlier identification of heart failure deterioration.

“For more than a century, the American Heart Association has been at the intersection of science, research, clinical expertise and innovation to drive improvements in cardiovascular and brain health,” said Nancy Brown, chief executive officer of the American Heart Association. “Through the Health Tech Competition, we continue that work by helping advance evidence-based solutions that address today’s most pressing health challenges and reach people where they live, work and receive care.” The statement reflects the program’s focus on extending care beyond hospitals and specialist offices. Technologies that can support patients at home, in workplaces or in under-resourced communities may be especially important when transportation, cost or geography limits access to traditional services.

The competition is also part of the Health Innovation Pavilion at Scientific Sessions, where scientific findings, clinical tools and commercial technologies will converge before an audience of researchers, physicians, entrepreneurs and investors. That setting gives finalists an opportunity to explain not only what their products do, but also how they were tested and how they could be incorporated into routine care. A successful system might combine wearable sensors, mobile applications, cloud-based analytics and clinician dashboards, but each component must contribute to a clear clinical objective. The value of a connected platform is ultimately measured not by the volume of data it generates, but by whether that information leads to earlier intervention, better decisions or healthier lives.

Previous Association programming has highlighted the growing global appetite for health technologies that can improve heart and brain health. The organization has recognized innovators working to address unmet clinical needs and has used its competition platform to bring young companies into contact with potential partners. By emphasizing evidence-based care, the 2026 program seeks to encourage responsible commercialization rather than the rapid deployment of unproven tools. This approach may also help investors and health systems distinguish between technologies that merely promise disruption and those with measurable clinical, operational or public-health benefits.

Applications and the full terms and conditions for the 2026 Health Tech Competition are available through the American Heart Association’s Center for Technology & Innovation. The finalists’ appearance at Scientific Sessions will offer a public test of how effectively emerging companies can translate technical innovation into practical care. As artificial intelligence, connected devices and remote monitoring become increasingly embedded in medicine, the competition illustrates a broader shift in health technology: the decisive question is no longer whether a system can generate sophisticated data, but whether it can produce trustworthy evidence and deliver meaningful improvements for patients with cardiovascular and brain conditions.

Subject of Research:
Health technology innovation, artificial intelligence, digital health, remote patient monitoring, cardiovascular disease and brain health.

Article Title:
American Heart Association Opens 2026 Health Tech Competition to Accelerate Cardiovascular and Brain Health Innovation

News Publication Date:
August 18, 2026

Web References:
https://ahahealthtech.org/aha-health-tech-competition-2026/
https://ahahealthtech.org/
https://professional.heart.org/en/meetings/scientific-sessions
https://newsroom.heart.org/news/houston-based-medical-technology-company-wins-overall-global-health-tech-competition-at-scientific-sessions-2025
https://newsroom.heart.org/news/finalists-named-in-global-health-technology-competition-to-advance-heart-and-brain-health

References:
Fahim YA, Hasani IW, Kabba S, Ragab WM. “Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives.” European Journal of Medical Research. 2025;30(1):848. doi:10.1186/s40001-025-03196-w. PMID: 40988064; PMCID: PMC12455834. https://pubmed.ncbi.nlm.nih.gov/40988064/

Keywords:
American Heart Association, Health Tech Competition 2026, cardiovascular health, brain health, artificial intelligence, digital health, remote patient monitoring, health innovation, clinical validation, stroke, heart failure, hypertension, Scientific Sessions 2026, medical technology, health care technology.

Initiated with an open call that attracted over 1,000 organizations, the UNITE programme received 19 ambitious proposals spanning various European regions. The submissions featured consortia comprising startups, scaleups, universities, research centers, hospitals, and healthcare providers, all collaborating to devise scalable digital health solutions. Following a rigorous multi-stage evaluation process, only three proposals were ultimately deemed worthy of implementation—underscoring the high competitive standards and the urgency for innovations capable of transcending fragmented healthcare landscapes.

The selected projects emphasize two critical areas in European healthcare strategy: the interoperable sharing of health data across borders and the advancement of personalized remote care. These are essential pillars in the face of unprecedented demographic shifts marked by ageing populations and intensified pressure on healthcare workforces. By addressing these challenges, UNITE’s chosen projects set the stage for transforming healthcare delivery through data-driven insights and patient-centric approaches.

Leading the cohort, CARDIO-HUB focuses on heart failure management, integrating real-world data with remote monitoring technologies to optimize care, particularly for elderly patients. This project leverages continuous clinical data capture and sophisticated analytics, aiming to improve early detection of cardiac events and to foster adaptive treatment protocols that respond dynamically to patient conditions.

NEODATA+ takes on the critical domain of neonatal intensive care. The project’s ambition lies in unlocking access to highly sensitive and complex datasets, enabling clinicians to make earlier, more precise diagnoses and intervention decisions for newborns in critical condition. Utilizing advanced data governance frameworks and ensuring privacy compliance, NEODATA+ promises to enhance neonatal outcomes by bridging data silos that have traditionally impeded cohesive clinical insights.

RAD-TRACK EU confronts the pervasive challenge of radiation exposure from medical imaging procedures. By designing a patient-centric data tracking system, this initiative ensures that radiation dosage histories follow patients as they move between healthcare providers. This breakthrough fosters safer imaging practices, mitigating cumulative exposure risks and promoting informed clinical decision-making grounded in comprehensive longitudinal data.

Together, these projects herald a significant evolution from isolated pilot initiatives toward full-scale deployment of digital health innovations across Europe. Historically, scaling digital health solutions has been hampered by regulatory fragmentation and technological inconsistencies. UNITE directly addresses these barriers by orchestrating harmonized interoperability standards, promoting alignment among regional health policies, and streamlining procurement processes for technology adoption.

Funded through a €20 million budget spread over four years, the UNITE programme is embedded within the European Commission’s Regional Innovation Valleys initiative. Spearheaded by 28DIGITAL, the project exemplifies a strategic investment in deep-tech innovation, aiming to empower startups and small to medium enterprises (SMEs) while revolutionizing healthcare infrastructures. This approach endeavors to bridge digital divides, ensuring equitable access to pioneering healthcare technologies irrespective of regional disparities.

Central to UNITE’s mission is the establishment of a unified European digital health ecosystem that transcends traditional borders. By enhancing data interoperability and fostering synergies among diverse innovation clusters, the initiative aspires to convert fragmented healthcare innovation landscapes into coordinated, cohesive networks. The programme’s inclusive methodology—encompassing open calls, capacity-building training modules, and ecosystem development activities—facilitates knowledge exchange and collaborative problem-solving at unprecedented scales.

Dr. Marina Samoylova, Programme Manager of UNITE, encapsulates the vision succinctly: “Europe possesses unparalleled data resources and expertise in digital health innovation. UNITE is the conduit that brings these elements together to scale impactful solutions across regions, ultimately delivering measurable benefits to healthcare systems and patients alike.” Her statement underscores the programme’s role as a catalyst for cross-border integration and real-world impact.

The implications of successful UNITE project implementation stretch far beyond technologically advanced pilot sites. By setting robust frameworks for data sharing and personalized care, these initiatives stand to revolutionize patient outcomes, optimize resource allocation, and invigorate healthcare workforce efficiency. The cross-pollination of insights emerging from interregional collaborations promises a ripple effect, inspiring further innovation and expanding the horizons of digital health.

Addressing both the technical and regulatory dimensions of digital health, UNITE’s model is emblematic of Europe’s broader ambition to lead global health innovation. The programme’s multi-faceted approach underscores the importance of harmonizing technical standards with ethical considerations such as data privacy and patient consent. This comprehensive strategy ensures that digital health advancements remain aligned with societal values and legal frameworks, cultivating trust and acceptance among all stakeholders.

This milestone in the UNITE initiative represents a clarion call for coordinated European action in digital health. By overcoming historical silos and fostering seamless data interoperability, the programme charts a course toward resilient, patient-centered healthcare ecosystems. As the selected projects transition to the implementation phase in spring 2026, the eyes of the digital health community will watch eagerly, buoyed by the promise of scalable, impactful innovation across Europe’s healthcare landscape.

(Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.)

Subject of Research: Digital health interoperability and personalized remote care innovations in European healthcare systems.

Article Title: Europe’s UNITE Initiative Pioneers Cross-Border Digital Health Solutions to Revolutionize Patient Care

News Publication Date: 16 April 2026

Web References:

• UNITE Initiative: http://unitedigihealth.eu/
• First UNITE Open Call: http://unitedigihealth.eu/open-call
• European Commission’s Regional Innovation Valleys: https://research-and-innovation.ec.europa.eu/new-european-innovation-agenda/new-european-innovation-agenda-roadmap/flagship-3-accelerating-and-strengthening-innovation-european-innovation-ecosystems-across-eu-and/regional-innovation-valleys_en
• 28DIGITAL: https://www.28digital.eu

Image Credits: UNITE Digital Health

Keywords: Digital health, interoperability, personalized medicine, remote patient monitoring, health data sharing, EU healthcare innovation, neonatal intensive care, cardiac monitoring, radiation tracking, cross-border healthcare, healthcare ecosystems, deep-tech, startup innovation

Parkinson’s disease, a progressive neurodegenerative disorder, is often characterized by motor symptoms such as tremors, rigidity, and bradykinesia. Tremors, particularly resting tremors, are among the earliest and most recognizable signs, significantly impacting patients’ quality of life. Traditional clinical assessments require patients to visit specialized centers where experts conduct in-person evaluations, frequently relying on subjective rating scales. These evaluations, while clinically informative, are limited by their episodic nature and potential observer bias.

Addressing these barriers, the team led by Hepp et al. introduced a wrist-worn device capable of continuously monitoring tremor characteristics using advanced accelerometer and gyroscope technologies. By embedding sensors that capture motion data with high temporal fidelity, the device enables quantifiable measurement of tremor amplitude and frequency throughout daily activities. This continuous data stream is then analyzed using validated algorithms to provide objective, fine-grained symptom profiles.

For the investigation, participants diagnosed with Parkinson’s disease were equipped with the wrist device and instructed to wear it during their normal routines at home. The researchers meticulously compared the tremor data extracted from the device to conventional clinical rating scales administered by movement disorder specialists. The results demonstrated remarkable concordance, affirming the device’s reliability in capturing tremor features consistent with clinical observations.

One of the most striking aspects of this study lies in its confirmation of validity—the extent to which the device measures exactly what it purports to. Validity was assessed through both concurrent and predictive methods, with the device successfully aligning with real-time clinical evaluations and accurately forecasting tremor fluctuations over extended periods. This reliability paves the way for its use as an effective tool not only for assessment but potentially for monitoring therapeutic interventions.

Such a technology addresses a critical need: the capability to remotely monitor Parkinson’s symptoms with high fidelity outside traditional clinical environments. Patients often experience symptom variability throughout the day, influenced by medication timing, stress levels, and activity. Capturing this dynamic symptomatology is essential for personalizing treatment plans but has been historically elusive. The wrist device’s capacity for continuous measurement opens new horizons in personalized medicine.

Moreover, the implications extend beyond simple symptom tracking. Real-time data may facilitate adaptive therapeutic approaches, where medications or stimulation therapies can be adjusted responsively to objective tremor severity metrics. This could lead to more stable symptom control and improved patient outcomes, reducing the burden of frequent clinic visits and subjective reporting inconsistencies.

The study also navigated challenges pertaining to device usability, including comfort for extended wear and data security—both paramount for patient adherence and privacy. The ergonomic design ensured minimal interference with daily activities, while data encryption protocols fortified patient data against breaches. These factors are instrumental in real-world adoption.

Delving into the technical framework, the wrist-worn device integrates inertial measurement units (IMUs) which detect multi-axis movements. Signal processing techniques, such as Fourier transformations, dissect the raw acceleration signals to identify tremor-specific frequencies typically within 3-7 Hz, characteristic of Parkinsonian tremors. This sophisticated analytical pipeline filters noise from voluntary movements, isolating pathological tremor patterns with high sensitivity.

Additionally, the study employed rigorous statistical analyses to ascertain measurement consistency—calculating intraclass correlation coefficients (ICCs) and Bland-Altman plots to verify inter-device and intra-subject reliability. These methods confirmed that repeated measures over time and across device units produced stable results, a critical aspect for longitudinal patient monitoring.

Importantly, the researchers underscored the utility of this technology in enabling remote clinical trials and research studies by providing continuous, standardized data streams unobtainable through traditional methods. Such data can deepen understanding of disease progression and responsiveness to novel pharmacological or device-based interventions.

Furthermore, the democratization of Parkinson’s disease monitoring through consumer-grade wrist devices promises to reduce healthcare disparities by increasing access to objective symptom assessment in under-resourced settings. Patients geographically distant from specialty centers could benefit from reliable data transmission to clinicians, enhancing care continuity.

While the study establishes a solid foundation for wrist-worn devices, the authors advocate for further research encompassing larger and more diverse cohorts. Additionally, integration with machine learning models could enhance tremor classification and predictive analytics, augmenting clinical decision-making capabilities.

In conclusion, the compelling evidence presented by Hepp et al. marks a significant advance in Parkinson’s disease management, bridging the gap between clinical symptomatology and real-world behavior through wearable technology. This innovation heralds an era wherein personalized, data-driven care is attainable, potentially improving the lives of millions grappling with the relentless challenges of Parkinson’s disease.

Subject of Research: Wrist-worn device technology for remote assessment of tremor in Parkinson’s disease patients.

Article Title: Added value of a wrist-worn device for assessing tremor in Parkinson’s disease: reliability and validity of tremor evaluation at home.

Article References:
Hepp, D.H., Ocran, K., Szanto, A. et al. Added value of a wrist-worn device for assessing tremor in Parkinson’s disease: reliability and validity of tremor evaluation at home. npj Parkinsons Dis. 11, 327 (2025). https://doi.org/10.1038/s41531-025-01163-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41531-025-01163-0